Therefore, the development of better biomarkers for the evaluation of NAFLD is needed to understand the underlying mechanism of action of SGLT2 inhibitors and other novel agents in the liver tissue. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.